Xolair

News
Novartis-AU-HQ

New dermatology licence for Xolair

Xolair has gained EU approval as the first ever add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients with inadequate response to H1-antihistamine tre